Compare Danaher Corporation (DHR) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Levi Strauss & Co. — how do they compare? Danaher Corporation trades at $217 (market cap $153.60B), while Levi Strauss & Co. trades at $19.01 (market cap $7.51B). The key difference: Danaher Corporation is far larger — about 20.5× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Levi Strauss & Co. for 70 Days on average.
| DHR | LEVI | |
|---|---|---|
Market Cap | $153.60B | $7.51B |
Volume | 3,974,063 | 17,462,954 |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $25.53 |
52-Week Low | $161.91 | $17.92 |
Typical Hold Time | 69 Days | 70 Days |
Enterprise Value | $175.81B | $9.06B |
Dividend Yield | 0.73% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Levi Strauss (LEVI) trades at $19.05, down 7.21% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.84, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights a '90s fashion revival benefiting the brand and the appointment of a new CFO effective November 2026. Cash flow trends have improved, with net cash flow turning positive in 2025 after prior volatility.
The outlook is positive given analyst consensus of a $27.80 price target and 79% buy ratings, though near-term price weakness and competitive pressures in apparel present risks. Earnings growth and direct-to-consumer expansion are key catalysts, but investors face execution risks and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
